Company Overview

Update
Headquarters:
La Jolla, CA
IPO:
Went Public on Aug 23, 2013
Stock:
NASDAQ:SPHS
Categories:
Biotechnology

Biotech focused on BPH treatment

Description

Update

Sophiris Bio Inc. (NASDAQ: SPHS) is a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), which it believes is an unsatisfied patient population with significant market potential. Sophiris is currently developing PRX302 for the treatment of BPH symptoms which is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. PRX302 is currently in Phase 3 clinical development with a blinded interim analysis expected in the second half of 2014 followed by a complete data analysis in the second half of 2015. For more information, please visit www.sophiris.com.

Current Team (5)

Update

Board Members and Advisors (1)

Update

Funding Rounds (2) - $35.20M

Update

Investors (1)

Update
  • 7c9d2e0ab2e1d753b382907e36d6019b

    Warburg Pincus

    Warburg Pincus LLC is a leading global private equity firm focused on growth investing. The firm..

Offices/Locations (1)

Update
  • Office

    1258 Prospect Street

    La Jolla, CA 92037

    USA

Images (1)

Update
  • 35800e8dc01fba86826b604a27d9e19d